psychopharmacoloty, psychodermatology, psychocutaneous medicine, Medicine
Abstract
When patients with psychodermatologic disorders present in clinic, the dermatologist can refer them to psychiatrists or other mental health care professionals. However, it is often the case that these patients will refuse a psychiatric referral because they either do not believe they have a disorder of psychiatric nature or they feel there is societal stigma associated with psychiatric illness. Therefore, it is essential for dermatologists to understand the common classifications for psychodermatological cases and to know how to optimally treat these patients with pharmacotherapy. The intent of this article is to help guide physicians in understanding the classifications of psychodermatological cases and in managing these conditions with pharmacotherapies. In this article, two classifications for psychodermatological cases are presented, followed by a discussion of medical therapies used to treat the main categories of psychopathologies that are more frequently encountered in dermatology. These include depression, anxiety, delusions, and obsessive-compulsive disorder.
Gordon, Kenneth B., Koo, John Y. M., Feldman, Steven R., Menter, Alan, Krueger, Gerald, Krueger, Gerald, Bagel, Jerry, Blauvelt, Andrew, Day, Robert M., Elder, J.T., Feldman, Steven R., Gottlieb, Alice, Koo, John Y. M., Lebwohl, Mark, Menter, Alan, Paller, Amy, Pariser, David, Stern, Robert, and Weinstein, Gerald
Koo, John Y. M., primary, Kowalski, Jonathan W., additional, Lebwohl, Mark G., additional, Kozma, Chris M., additional, Menter, M. Alan, additional, and Ellis, Charles N., additional
Butler, Daniel C., primary, Simpson, Eric, additional, Guttman-Yassky, Emma, additional, Eichenfield, Lawrence F., additional, Golant, Alexandra K., additional, Koo, John Y. M., additional, Armstrong, April W., additional, Alexis, Andrew F., additional, Lio, Peter A., additional, Marson, Justin W., additional, and Lebwohl, Mark, additional
Heller, Misha M., Wong, Jillian W., Lee, Eric S., Ladizinski, Barry, Grau, Manuel, Howard, Josephine L., Berger, Timothy G., Koo, John Y. M., and Murase, Jenny E.
Brownstone, Nicholas D., primary, Reddy, Vidhatha, additional, Thibodeaux, Quinn, additional, Chan, Stephanie, additional, Myers, Bridget, additional, Bhutani, Tina, additional, and Koo, John Y. M., additional
Weinstein, Gerald D., Koo, John Y. M., Krueger, Gerald G., Lebwohl, Mark G., Lowe, Nicholas J., Menter, M. Alan, Lew-Kaya, Deborah A., Sefton, John, Gibson, John R., and Walker, Patricia S.
Strauss, John S., Gottlieb, Alice B., Jones, Terry, Koo, John Y. M., Leyden, James J., Lucky, Anne, Pappas, Anastasios A., McLane, John, and Leach, Eileen E.
Butler, Daniel C., Simpson, Eric, Guttman-Yassky, Emma, Eichenfield, Lawrence F., Golant, Alexandra K., Koo, John Y. M., Armstrong, April W., Alexis, Andrew F., Lio, Peter A., Marson, Justin W., and Lebwohl, Mark
Subjects
ATOPIC dermatitis, ECZEMA, HETEROGENEITY
Abstract
HT
Atopic dermatitis (AD) is a condition with varied clinical presentations and heterogeneous phenotypes. While the Hanifin-Rajka criteria [[3]] improved diagnosis of AD for research, the clinical challenge has become differentiating which dermatoses are classic AD, atypical variants of AD, or distinct clinical entities unrelated to AD. Recognizing the clinical heterogeneity in patients with atopic related skin conditions in order to improve therapeutic decision-making and outcomes: an expert panel consensus statement. [Extracted from the article]
Malakouti, Mona, primary, Brown, Gabrielle E., additional, Leon, Argentina, additional, Wang, Eva, additional, Naegeli, April N., additional, Edson-Heredia, Emily, additional, Levin, Ethan, additional, and Koo, John Y. M., additional
Ladizinski, Barry, Busse, Kristine L., Bhutani, Tina, and Koo, John Y. M.
Subjects
Aripiprazole -- Usage, Aripiprazole -- Health aspects, Delusions -- Risk factors, Delusions -- Diagnosis, Delusions -- Care and treatment, Delusions -- Patient outcomes, Delusions -- Case studies, Health, Pharmaceuticals and cosmetics industries
Abstract
ABSTRACT Delusions of parasitosis (DOP) is a psychiatric disorder characterized by the fixed false belief that one is infested with parasites or other organisms. Historically, pimozide, a first-generation antipsychotic, has [...]
Background. Patients with moderate-to-severe psoriasis are often treated with systemic immunosuppressant agents that decrease immune system function. For the elderly, these medications are often problematic due to their already immunosuppressed state and comorbidities. However, there are few studies examining the effects of these medications on the elderly age group. Therefore, there is often discomfort among dermatologists treating elderly patients with psoriasis in utilizing systemic agents, frequently resulting in inadequate treatment. Objective. We review the safety profiles of systemic treatments often used to treat psoriasis and their possible adverse risks to the geriatric population. Methods. We conducted a search of PubMed’s Medline database of articles published from 2000 to 2011, which resulted in 14 articles. Conclusion. Treating geriatric patients with moderate-to-severe psoriasis remains a challenge due to immunosenescence and comorbidities. More studies focusing on psoriasis treatment safety in the geriatric population are needed.
Malakouti, Mona, Brown, Gabrielle E., Leon, Argentina, Wang, Eva, Naegeli, April N., Edson-Heredia, Emily, Levin, Ethan, and Koo, John Y. M.
Subjects
SKIN diseases, DERMATOLOGY, INTIMACY (Psychology), HUMAN sexuality, QUALITY of life, SOCIAL stigma
Abstract
Introduction:Patient-reported outcome measures are increasingly utilized in dermatology to assess the impact of skin disease on quality of life. Despite recognition of the influence of skin disease on intimate relationships, an instrument to assess intimacy has not been developed. The objective of this study was to create the dermatologic intimacy scale (DIS) and administer the prototype to a patient population. Methods:A group of healthcare providers at the University of California San Francisco created the DIS prototype. A total of 1676 psoriasis patients of an online community were invited to complete a cross-sectional survey including demographic information, DIS, body surface area (BSA) and anatomical involvement. Results:A total of 1109 patients completed the survey in its entirety. Patients with moderate-to-severe psoriasis (BSA ≥3%) had a higher DIS score overall and for each individual question than patients with mild disease (BSA < 3%;p < .001). Patients with genitalia, nails, face, neck and scalp involvement had higher scores compared to patients without involvement (p < .001). Conclusions:Patients with more extensive disease and specific anatomical involvement experience a greater impact on intimacy. Interpretation is limited by patient response rate, as patients with or without intimacy issues may be more or less likely to respond. Further analysis is necessary for validation and interpretation. [ABSTRACT FROM PUBLISHER]
Koo, John Y. M., Lee, Chai Sue, Lebwohl, Mark, Koo, John Y. M., Lee, Chai Sue, and Lebwohl, Mark
Subjects
Psoriasis
Abstract
Using a practical and problem-focused approach, this updated, full-color Second Edition of Mild-to-Moderate Psoriasis equips dermatologists, internists, family practitioners, and residents with a state-of-the-art guide to the clinical management of mild-to-moderate psoriasis. Written by an international team of key opinion leaders, this resource ex
Written by experts in the dermatology field, the new Third Edition of Moderate-to-Severe Psoriasis discusses the current use of biologics and new pharmacologic and phototherapy treatments for moderate-to-severe psoriasis. With 80 high quality color figures and full color throughout, this stand-alone text emphasizes safe and effective treatments for